| Chris received a BS degree in Animal Science and an MS degree in Biochemistry from the University of New Hampshire followed by a Ph.D. in Biochemistry from the University of California at Davis. Chris joined Wyeth (now Pfizer) in July 2002 after working at Biogen in the Process Biochemistry group for seven years. Chris has led numerous early and late phase development programs within Bioprocess Research & Development (BRD) at Pfizer, and supported the development of manufacturing processes for many projects ranging from recombinant proteins and blood factors to gene therapy. Chris is considered a viral clearance SME within BRD and has contributed to the development and implementation of a modular viral clearance package that has enabled an accelerated early development path for many of Pfizer’s antibody projects. |